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Objective. Determine the potential of procalcitonin (PCT) to predict neurological outcome after hypothermia treatment following
cardiacarrest.Methods.Retrospectiveanalysisofpatientdataovera2-yearperiod.Mortalityandneurologicaloutcomeofsurvivors
were determined 6 months after cardiac arrest using the Cerebral Performance Category (CPC) score. Results.D a t af r o m5 3
consecutive patients were analyzed. Median age was 63 (54–71) and 79% were male. Twenty-seven patients had good outcome
(CPC≤2) whereas 26 had severe neurological sequelae or died (CPC 3–5). At 48h, after regaining normothermia, PCT was
signiﬁcantly higher in patients with bad outcome compared to those with good outcome: 3.38 (1.10–24.48) versus 0.28 (0–
0.75)ng/mL (P<0.001). PCT values correlated with bad neurological outcome (r = 0.54, P = 0.00004) and predicted outcome
with an area under the curve of 0.84 (95% CI 0.73–0.96). A cutoﬀ point of 1ng/mL provided a sensitivity of 85% and a speciﬁcity
of 81%. Above a PCT level of 16ng/mL, no patient regained consciousness. PCT provided an additive value over simpliﬁed acute
physiology score II. Conclusions. PCT might be an ancillary marker for outcome prediction after cardiac arrest treated by induced
hypothermia.
1.Introduction
Successful cardiopulmonary resuscitation after sudden car-
diac arrest (CA) is followed by the early development of
a systemic inﬂammatory response syndrome, characterized
by an increase of serum markers of inﬂammation includ-
ing C-reactive protein (CRP), tumor-necrosis factor alpha,
interleukin-6, and procalcitonin (PCT) [1].
In patients with sepsis, PCT has been shown to be a
speciﬁc marker of bacterial infection, a valuable tool to guide
antibiotic therapy, and a predictor of sepsis-associated mor-
tality [2–4]. In contrast, during the early postresuscitation
phase following cardiac arrest the diagnostic value of PCT
to assess infection is poor [5, 6]. It has been suggested that
the increase of PCT is mainly the result of the severity of
the postresuscitation disease itself and elevated PCT levels
have been associated with an unfavourable outcome in these
patients [1, 2, 7, 8].
Mild therapeutic hypothermia (MTH) has been shown
to improve neurologic outcome after CA in several studies
but may modulate the serum PCT concentration and its
utility as an outcome-predictive marker [9–11]. PCT values
of 0,5ng/mL one day after hospitalization were found
to be highly predictive for bad neurological outcome in
patients after CA without the use of MTH [7]. How-
ever, in a second study, PCT values 24 hours after ICU
admissionvariedlargelywhencomparingpatientssubmitted
to MTH to normothermic patients [12]. Additionally, no
diﬀerences between the groups were found when the PCT
measurements were repeated 120 hours after ICU admission.2 Critical Care Research and Practice
They concluded that MTH seems to have a remarkable
impact on the inﬂammatory response after CA. In their
study,PCTlevelsafter24hourswerethesinglebestpredictor
for bad neurological outcome. However, calculating cutoﬀ
values for PCT to predict bad outcome was hampered by
the large inﬂuence of MTH on PCT serum concentration.
To avoid the eﬀect of residual MTH, we performed mea-
surements of serum PCT in patients following cardiac arrest
24 hours after the cessation of hypothermia as a marker for
long-term neurological outcome.
2.MaterialsandMethods
This cohort study was conducted in an 18-bed mixed inten-
sivecareunit(ICU)ofanacademictertiarycarecentrelinked
to the national institute for cardiosurgery and interventional
cardiology of Luxembourg. This investigation was approved
by the National Ethics Committee of Luxembourg and
writteninformedconsentfromthenextofkinofeachpatient
was obtained prior to study inclusion.
All adult patients (age >18 years) with primary cardiac
arrest and successful resuscitation with an initial Glasgow
coma score (GCS) <8 were eligible for the study. Tra-
cheal intubation, mechanical ventilation, and sedation were
mandatory for every patient. Patients with cardiac arrest
following trauma, patients with known severe neurological
disorders or stroke, head injury, or patients with end-stage
noncardiac disease were excluded.
PriortothetransfertoourICUpatientsweresubjectedto
coronary intervention according to published international
guidelines [13]. Induction of MTH was started immediately
after admission to the hospital according to published
recommendations for the use of MTH after CA [14]. Brieﬂy,
hypothermia was induced at hospital admission using a
combination of cold i.v. ﬂuid infusion, surface cooling by
ice packs and intravascular cooling (Coolgard with Icy-cath
ZOLL Circulation, CA, USA) [15]. Target core (bladder)
temperature was 33◦C in all patients. After 24h, rewarming
was done actively using the i.v. cooling device at a rate of
0.2◦C/h to achieve a core temperature of 36◦Ca t4 8h o u r s
after cardiac arrest at the latest.
Arterial blood samples were collected 48h after cardiac
arrest for measurement of procalcitonin (PCT), C-reactive
protein (CRP), and white blood cells (WBC). The samples
were immediately processed in the central hospital labora-
tory.
No decision to withdraw or withhold treatment in
patients remaining unconscious was taken until sedation was
completelystoppedforatleast5days.Thereafter,therapeutic
limitations were implemented for patients presenting one or
more predeﬁned signs of bad neurological outcome: ﬁxed
pupils, seizures, no motor response, absence of somatosen-
sory evoked potentials, and major signs of hypoxic brain
damage on CT-Scan or MRI [16].
2.1. Data Collection. All pre- and intrahospital data were
collected retrospectively from the ﬁles of the patients and
were recorded according to the Utstein-style template [17].
Only patients with complete datasets were included in the
study.
PCT was measured using an electrochimiluminescent
immuno assay (ECLIA; B.R.A.H.M.S. AG, Henningdorf,
Germany)ontheCobase601analyzer(Roche,Basel,Switzer-
land). A Modular analytics P module (Roche, Basel, Switzer-
land) was used to determine CRP by immunoturbidimetry
using 3rd-generation CRP Tina-quant reagent (Roche, Basel,
Switzerland). The functional sensitivity for PCT and CRP
testing was 0.09ng/mL, respectively, 0.6mg/L. WBC was
determined automatically by the Advia 2120 Haematology
system (Siemens, Erlangen, Germany). Only values from
samples free of haemolysis were used for this study.
Pneumonia was deﬁned as new or progressive inﬁltrate
on the chest X-ray, leucocytosis (>12000 cells/mm3), puru-
lent tracheal aspiration, and microbacterial conﬁrmation of
tracheal aspirates.
Sepsis was deﬁned as heart rate >100/min, WBC >12000
cells/mm3 or <4000 cells/mm3, the clinical evidence or
microbiological proof of an infection and hypotension (sys-
tolic blood pressure <90mmHg) with need for vasopressor
despite ﬂuid therapy. In contrast to current guidelines, body
temperature and respiratory rate were not included in the
deﬁnition,sinceallpatientsweremechanicallyventilatedand
subjected to MTH.
Cardiogenic shock was deﬁned as a systolic blood
pressure <90mmHg despite ﬂuid replacement, the need for
inotropes,vasopressors,andtheneedforintra-aorticballoon
pump (IABP) without evidence of infection.
Neurological outcome was assessed by the Cerebral
Performance Category (CPC) score by physicians unaware
of the blood tests and implicated neither in the treatment of
the patient nor in this study [18]. The CPC score classiﬁes
patients after CA into 5 categories: CPC 1 (no neurological
disability), CPC 2 (minor neurological deﬁcit), CPC 3
(severe neurological impairment, dependent in everyday
life), CPC 4 (coma), and CPC 5 (dead). CPC data collected 6
months after cardiac arrest were considered for outcome.
Primary end point of this study was the correlation of
PCT values at 48 hours after CA with neurological outcome
at 6 months.
Secondary endpoints were the correlation of CRP and
WBC values at 48h after CA with neurological outcome at
6 months.
2.2. Data and Statistical Analysis. Continuous variables are
expressed as median and interquartile range (IQR) and
categorical variables are expressed as count and proportions,
unless stated otherwise. All datasets were subjected to
the Shapiro-Wilk normality test before statistical analysis.
Comparisons between 2 groups of continuous variables
were performed using t-test for data following a Gaussian
distribution and Mann-Whitney test for non-gaussian data.
Fisher’s exact test was used for categorical variables. Cor-
relation between outcome and PCT, CRP, and WBC was
estimated using the Spearman test. The area under the
receiver operating characteristic curves (AUC) was used for
prediction capacity evaluation. Multiple logistic regression
models were implemented to investigate the predictiveCritical Care Research and Practice 3
Table 1: Main demographic and Utstein data.
Good outcome (n = 27) Bad outcome (n = 26) P
Age (years) 61 (49–68) 67 (59–72) 0.06
SAPS II 59 (52–66) 72 (66–77) <0.0001
Male (n) 23 (85%) 19 (73%) 0.23
OHCA (n) 20 (74%) 20 (80%) 0.53
Time to ROSC (min) 20 (10–30) 30 (23–36) 0.005
Time CA to TT (min) 280 (215–340) 285 (176–335) 0.73
Initial rhythm 0.20
VF/VT 23 (85%) 12 (46%)
Asystole 2 (7.5%) 8 (31%)
PEA 2 (7.5%) 6 (23%)
Cardiogenic shock (n) 7 (26%) 14 (54%) 0.04
Coronary intervention (n) 24 (89%) 21 (81%) 0.41
Pneumonia (n) 12 (44%) 8 (31%) 0.30
Sepsis (n) 3 (11%) 2 (7.7%) 0.68
Antibiotics treatment (n) 25 (93%) 14 (54%) 0.001
SAPS simpliﬁed acute physiology score; OHCA out of hospital cardiac arrest; ROSC return of spontaneous circulation; CA cardiac arrest; TT target
temperature; VF/VT ventricular ﬁbrillation/ventricular tachycardia; PEA pulseless electric activity.
Table 2: Biological parameters at 48h after CA.
Good outcome (n = 27) Bad outcome (n = 26) P
PCT (ng/mL) 0.27 (0–0.72) 3.7 (0.84–31.65) <0.001
CRP (mg/L) 94 (79–157) 139 (107–175) 0.12
WBC (cells/mm3) 9530 (7235–12935) 12460 (9450–17550) 0.18
PCT procalcitonin; CRP C-reactive protein; WBC white blood cell count.
value of multiple clinical parameters. A P value <0.05 was
considered signiﬁcant.
Statistical analysis was performed using SigmaPlot (Sys-
tat Software Inc., CA, USA) and StAR (http://protein.bio
.puc.cl/star.html)s o f t w a r e .
Sample size calculation reported a minimum number
of patients of 30 to detect a signiﬁcant correlation between
outcome and PCT (correlation coeﬃcient 0.5, desired power
0.8, signiﬁcance threshold 0.05).
3. Results
Between April 2008 and June 2010, 68 consecutive adult
patients subjected to MTH after successful cardiopulmonary
resuscitation were admitted to our ICU. Five patients died
during the ﬁrst 48h after admission, nine patients did
not have the full dataset available, and one patient had
no informed consent signed. Therefore, 53 patients were
included in the analysis. The median age was 63 (54–71)
years and 42 patients (79%) were male. Cardiac arrest was
caused by a cardiac aetiology in 43 (81%), by respiratory
failure in 5 (9.5%) and by other nontraumatic causes
in 5 (9.5%) patients. The initial rhythm was ventricular
ﬁbrillation or pulseless ventricular tachycardia in 35 (66%)
patients and asystole or pulseless electric activity in 18 (34%)
patients. Out of hospital cardiac arrest (OHCA) occurred in
40 (75%) patients and in hospital cardiac arrest (IHCA) in
13 (25%) patients.
Patients were dichotomised into two groups according to
their CPC score 6 months after CA. Patients were considered
having a good neurological outcome when CPC was 1-
2 while the patients in the group with bad neurological
outcome displayed a CPC score of 3–5.
Demographic and Utstein-style data are presented in
Table 1. Bad outcome group patients had a higher SAPS II
Score, an increased time to reestablish a suﬃcient spon-
taneous circulation and a higher incidence of cardiogenic
shock. Eighteen patients in the bad outcome group died after
6 (5–12) days during the ICU stay. At 6 months, 22 out of 26
patients (85%) of the bad outcome group had died (8 (6–19)
days afterCA) and 4 patients survived with severe neurologic
impairment (CPC3). No patient stayed comatose.
The incidence of pneumonia and sepsis was similar
in both groups. Nevertheless, antibiotic use was higher in
survivors than in nonsurvivors. There was no signiﬁcant
diﬀerence in PCT at 48h in patients with pneumonia versus
no pneumonia (0.70 (0–1.71)ng/mL versus 1.30 (0.22–
8.31)ng/mL, P = 0.15), respectively, sepsis versus no sepsis
(1.18 (0.17–78.05)ng/mL versus 0.85 (0.19–3.75)ng/mL,
P = 0.59).
PCT,CRP,andWBClevelsat48hoursaftercardiacarrest
are displayed in Table 2. The median PCT value for all the4 Critical Care Research and Practice
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Figure 1: PCT values according to outcome. Patients with bad
outcome have signiﬁcantly higher PCT levels than patients with
good outcome. Log10-transformed data are shown.
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Figure 2: ROC curve showing the signiﬁcant prognostic value of
PCT for neurological outcome.
patients was 0.86 (0.19–3.85)ng/mL. Survivors in the good
outcome group displayed signiﬁcantly lower PCT values
than patients with bad neurological outcome (Figure 1, P<
0.001). There was a signiﬁcant correlation between PCT val-
ues and bad neurological outcome (r = 0.54, P = 0.00004).
A receiver operating characteristic curve (ROC) analysis
revealed a capacity of PCT to predict neurological outcome
with an AUC of 0.84 (95% CI 0.73–0.96; P<0.0001;
Figure 2). A cutoﬀ point of 1ng/mL provided a sensitivity
of 85% (95% CI 0.66–0.96) and a speciﬁcity of 81% (95%
CI 0.61–0.93, FPR 7%). The positive predictive value was
82%andthenegativepredictivevaluewas85%.AboveaPCT
level of 16ng/mL, no patient regained consciousness, which
generates a sensitivity of 100% (95% CI: 0.87–1.00).
No signiﬁcant correlation was found between CRP and
WBC on one hand and PCT on the other hand.
Finally, we investigated the predictive value of PCT in
relationship with other clinical parameters such as simpliﬁed
acute physiology score II (SAPS II), cardiogenic shock,
and time to return of spontaneous circulation (ROSC), all
known to aﬀect outcome after cardiac arrest. Using multiple
logistic regression models, we observed that SAPS II was
the best predictor of outcome (P<0.001). PCT as well-
predicted outcome (P = 0.03), and provided an additive
v a l u eo v e rS A P SI Ia ss h o w e db ya ni n c r e a s eo fR2 values
from 0.29 to 0.36 when PCT was added over SAPS II
prediction.
4. Discussion
The purpose of the present study was to investigate the
potentialassociationofserumPCTlevels48haftersuccessful
resuscitation with MTH and neurological outcome after six
months in patients following CA. We found increased PCT
levels to be a strong predictor of bad neurological outcome
with a threshold value of 1ng/mL providing a speciﬁcity of
84%. At a level of 16ng/mL, PCT predicted bad outcome
with a sensitivity of 100%. There was no association between
CRP or WBC and neurological outcome.
A marked increase of a variety of proinﬂammatory
cytokines in patients successfully resuscitated after cardiac
arrest has been described by several authors. This increase
has repeatedly been found to be time-dependent and more
pronouncedinnonsurvivorsthaninsurvivors,indicatingthe
potential utility of these mediators as biomarkers to predict
outcome in this patient group [1]. Additionally, biomarkers
canbeusefultomonitortheevolutionofsystemicinﬂamma-
tion as a consequence of infection. This may apply especially
to patients after cardiac arrest. Following successful resusci-
tation they may require subsequent sedation and mechanical
ventilation over a prolonged time period, especially when
they are submitted to MTH. Although considered beneﬁcial,
hypothermia, and mechanical ventilation may increase the
risk to develop pneumonia and other types of infection
making an improved surveillance desirable [19, 20].
Recently, procalcitonin has been shown to be a valuable
marker to detect bacterial infection, guide antibiotic therapy,
and predict outcome in patients with pneumonia and other
causesofseveresepsis[2,21,22].Incontrast,procalcitoninis
onlyapoorpredictorofbacterialpneumoniainpatientsafter
cardiac arrest due to a pronounced but unspeciﬁc increase
of its serum level in the early course of postresuscitation
inﬂammation. In a study by Mongardon et al. 86 out of 132
included patients developed pneumonia [5]. During the ﬁrst
three days, PCT values in these patients were signiﬁcantly
higher than in those without pneumonia. However, using a
threshold of 0.5ng/mL the positive predictive value at day
1 was only 68%, making PCT a rather poor predictor for
infection in this setting. Similar results were reported by
Schuetz et al. [6]. In a retrospective study on 35 patients after
cardiac arrest they found PCT to peak without any statistical
diﬀerence during the ﬁrst 24 hours in all patients with or
without pneumonia. In contrast, in a earlier study by Oppert
et al. the authors observed that an increase of PCT can
indicate the onset of ventilator-associated pneumonia, usingCritical Care Research and Practice 5
ac u t o ﬀ value of 1ng/mL during the ﬁrst seven days [23].
In our study we did not investigate speciﬁcally the ability of
PCT to indicate the onset of infection. However, we did not
ﬁndanydiﬀerenceofserumPCTlevelsbetweenpatientswith
and without sepsis or pneumonia.
When interpreting the results of the diﬀerent studies,
severalaspectsshouldbetakenintoaccount.First,thepoten-
tial cutoﬀ value of PCT to indicate nosocomial pneumonia
lies in exactly the same range of the PCT values observed
in patients after cardiac arrest. In a mixed group of ICU
patientsCharlesetal.foundacutoﬀvalueof0.44ngPCT/mL
to detect nosocomial pneumonia at the day of its onset
with a speciﬁcity of 83.0% [24]. Mean PCT in patients
after cardiac arrest but without signs of pneumonia was
0.18ng/mL (0.11–0.81) at admission and 1.03ng/mL (0.45–
4.68)atday1[5].ThesedatamaysupportdoubtsthataPCT-
baseddiﬀerentiationbetweeninfectionandpostresuscitation
inﬂammation may be possible. Second, combining PCT
with other signs of infection or scores to achieve a more
precise diagnosis of infection may be diﬃcult since classical
signs of infection like fever are abolished by MTH. For
the same reason the deﬁnitions of sepsis and pneumonia
used in our study were only in part applicable. Third,
comparison of results from earlier studies may additionally
be hampered by a low accuracy of older PCT assays. The
assay used in our study has a lower limit of detection of
0,02ng/mL [25].
Due to its increase after cardiac arrest, PCT has also
been tested as a biomarker to predict outcome following
successful resuscitation. Most interestingly, PCT has recently
been identiﬁed not only as a biomarker, but as an active
part of the deleterious inﬂammatory cascade and therefore
as a potential therapeutic target [26]. In an earlier study,
Fries et al., found a cutoﬀ value of 0,5ng/mL at day 1 to
be predictive for a bad neurological outcome after cardiac
arrest in normothermic patients [7]. In a more recent study,
the same group investigated the eﬀect of MTH on PCT
evolution during the early course of the disease [12]. They
observed a strong correlation between bad neurological
outcome and increased PCT plasma levels 24 hours after
cardiac arrest. This increase was even more pronounced
when patients were not submitted to MTH. These data
suggest a strong inﬂuence of MTH on serum PCT levels
making it questionable whether PCT values obtained during
hypothermia can be used to predict outcome. In our study,
to avoid a potential impact of MTH, PCT was measured
48 hours after cardiac arrest when all patients had regained
normothermia. However, additional studies are required to
understand the exact inﬂuence of MTH on PCT liberation
andwhethermodulationoftheinﬂammatoryresponsecould
actually be beneﬁcial.
More than just being a marker for neurological outcome,
it appears that PCT is more likely to reﬂect the severity of the
ischemic insult eventually resulting in severe organ damage
(including the brain) and perhaps death. Therefore, PCT
might be a marker of the severity of the postcardiac arrest
syndrome[1,5,27].PCTcouldbeamissinglinkbetweenthe
neurological tests (clinical examination, electrophysiology,
and brain biomarkers) and the general condition of the
patient. As PCT broadens the biomarker spectrum to
the whole organism, and is not limited to the brain, it
could potentially allow a more accurate prognostication of
outcome after cardiac arrest [28, 29]. This may also be
reﬂected by signiﬁcantly higher SAPS II values, a longer time
to return of spontaneous circulation, and a higher incidence
of cardiogenic shock in the bad outcome group of our study.
We further positioned PCT in a multiple logistic regression
model as an ancillary marker for outcome prediction when
combined with SAPS II. Although SAPS II in itself is a
very strong predictor for bad outcome in these patients,
addition of PCT may help to even strengthen its value for
outcomeprediction.PCTmustnotbeusedassingleoutcome
predictor but should always be considered in a bundle with
other prognostic tools.
Neurological outcome in our study was evaluated at 6
months to assure a stable neurological situation and avoid
underestimation of the patients’ recovery [30]. In fact, only
4 patients in the bad outcome group survived more than
6 months with persisting severe neurologic impairment. In
the studies by Fries and coworkers neurological outcome
was tested at day 14 after cardiac arrest [7, 12]. In a third
study investigating the predictive value of PCT neurological
outcome after CA, hypothermia was only applied in 7 out
of 21 patients [8]. No analyses separating patients submitted
to hypothermia form those treated with normothermia to
evaluate the impact of MTH have been performed. Mean
PCT at 12 and 24 hours after CA was signiﬁcantly higher in
patients with unfavourable outcome when compared to the
group with a favourable neurological evolution.
Our study clearly has some limitations. As a single centre
retrospective trial it has to deal with all inherent risks of bias
of this study type. Although a sample size calculation has
been done, we must acknowledge that the sample size of our
study population might still be too small to be deﬁnitively
conclusive. Our ﬁndings and hypothesis clearly require to be
veriﬁedinalarger,multicentreandinvestigator-blindedtrial.
We included IHCA and OHCA as well as all types of
initial rhythms as we think that a prognostic marker after
cardiac arrest should neither be inﬂuenced by the location of
cardiac arrest nor the initial rhythm to be universally used.
We only studied PCT values at 48 hours after CA, as this
was part of the blood sampling protocol of the study. As no
PCT values before or beyond this time point were available,
we might have missed other time points with signiﬁcant
diﬀerences between groups to predict outcome or potential
eﬀects of MTH [5, 6].
5. Conclusions
In this small study of 53 cardiac arrest patients treated with
MTH, we found that PCT, measured 48 hours after cardiac
arrest, might be an ancillary predictor for the 6-month
outcome after successful resuscitation. A cutoﬀ value above
1ng/mL predicted bad outcome with an accuracy of 84%.
Above 16ng/mL, PCT predicted bad outcome with a 100%
sensitivity (95% CI: 0.87–1.00). Sequential measurements of
PCT in larger multicentre trials are required to conﬁrm these
ﬁndings.6 Critical Care Research and Practice
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